The effect of somatostatin on the rise of growth hormone and glucagon secretion induced by arginine and L-dopa in diabetic patients.
The growth-hormone-release-inhibiting hormone somatostatin was infused in seven juvenile diabetic subjects during an arginine infusion test and in six juvenile diabetic subjects during an L-dopa stimulation test. The plasma growth hormone response to arginine and L-dopa was completely inhibited by somatostatin. The plasma pancreatic glucagon response to arginine was also inhibited by somatostatin. The plasma pancreatic glucagon level was not changed by L-dopa, but somatostatin induced a significant fall in this level. The plasma glucose increase after arginine and L-dopa administration was slightly inhibited by somatostatin. The arginine-induced fall in free fatty acids was prevented by somatostatin, and the L-dopa-induced rise in free fatty acids was enhanced by somatostatin. The growth hormone- and glucagon-surppressive effect of somatostatin may prove useful in controlling the metabolic state and in preventing the development of angiopathy in diabetic patients. A somatostatin preparation with prolonged activity is needed for lifelong administration, but the presently available compound may be of value as an adjunct in the standard treatment of diabetic ketoacidosis and coma.
D001120:Arginine / Q000494:pharmacology*; D001786:Blood Glucose / Q000378:metabolism; D003864:Depression, Chemical; D003920:Diabetes Mellitus / Q000097:blood*; D005230:Fatty Acids, Nonesterified / Q000097:blood; D005934:Glucagon / Q000097:blood*; D013006:Growth Hormone / Q000097:blood*; D006801:Humans; D007980:Levodopa / Q000494:pharmacology*; D013004:Somatostatin / Q000494:pharmacology*; D013268:Stimulation, Chemical
D001786:Blood Glucose; D005230:Fatty Acids, Nonesterified; D007980:Levodopa; D013004:Somatostatin; D013006:Growth Hormone; D005934:Glucagon; D001120:Arginine